Quantity of eligible individuals: CDEC mentioned the uncertainty in the quantity of clients with reasonably significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some clients who're classified as having mild or average sickness could have a severe bleeding phenotype, which https://andrezehfd.ampblogs.com/considerations-to-know-about-hemgenix-72488896